Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Janssen-Cilag G.m.b.H | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the present study is to estimate the national annual prevalence and incidence of current hepatitis C virus (HCV) infections among opioid dependent individuals in opioid substitution treatment (OST) based on a representative sample of approximately 2,500 outpatients in 100 substitution facilities across Germany. Furthermore, the study aims to describe factors influencing HCV therapy initiation and seroconversion during OST.
In this non-interventional, observational, longitudinal study, data is collected at two time points. The primary outcome measures HCV prevalence and incidence will be based on documentation from routine patient care at baseline and 12-month follow-up. Secondary outcome measures will be investigated by means of surveys of opioid substituted patients and their clinicians (completed at baseline), as well as data from routine patient care.
The sample size calculation is based on the primary outcome variable of HCV incidence among OST patients. The literature reports an HCV incidence of about 4/100 person-years +/- 2 new infections per 100 person-years in this target group. For a partial sample size of (at least) 32 patients with HCV seroconversion and an observation period of 1 year, 800 HCV antibody-negative patients are needed as an initial group for observation. Assuming an HCV antibody prevalence of 68% among OST patients, 2500 patients are needed in total (32% corresponds to N = 800).
Recruitment of clinicians is conducted via the national Substitution Registry in which all clinicians in Germany, who hold a qualification to prescribe substitution medication, are registered. To ensure that all substituting clinicians in Germany are considered in the present study, the investigators sent study invitations to all 3,356 addresses in the Substitution Registry as of 31.12.2013. Of the clinicians eligible for participation, a representative sample of clinician is drawn according to two criteria: 'German Federal State' (GFS) and 'Number of Patients Per Clinician' (PPC). Using the SPSS Complex Samples Procedure, clinicians are stratified by GFS and PPC, such that each GFS is represented at least once, and such that the same proportions of clinicians per GFS and per PPC category are achieved (to the best of our ability) as in the total sample of clinicians registered in the Substitution Registry.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HCV negative or in HCV treatment at T1 | This group will be followed up at T2 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| National annual prevalence and incidence of current HCV infections among opioid dependent individuals in substitution treatment | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Patient questionnaire: Patient Reported Outcomes | Quality of Life, Health-Related Quality of Life (SF-12), Physical health (OTI), Mental health (BSI-18), Autonomy preference (API-Dm), Satisfaction with care (ZAPA), Knowledge, needs and attitudes towards infectious diseases, HCV treatment and treatment experiences | 1 month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Opioid dependent outpatients in opioid substitution treatment regardless of treatment setting
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jens Reimer, Prof. Dr. | University Medical Center Hamburg-Eppendorf, Centre for Interdisciplinary Addiction Research (CIAR), Hamburg University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr. Rudolf Dinkelacker | Crailsheim | Baden-Wurttemberg | 74564 | Germany | ||
| Dr. Manfred Hartmann |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30606188 | Derived | Strada L, Schmidt CS, Rosenkranz M, Verthein U, Scherbaum N, Reimer J, Schulte B. Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study. Subst Abuse Treat Prev Policy. 2019 Jan 3;14(1):2. doi: 10.1186/s13011-018-0187-9. | |
| 26653754 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Oct 1, 2019 | |
| Reset | Oct 23, 2019 | |
| Release | Dec 7, 2023 |
Not provided
Not provided
Not provided
Not provided
| Clinician questionnaire: Clinician Reported Outcomes and Data from Routine Patient Care |
Substitution treatment, HCV diagnostic and treatment, Consumption of substances, Physical and mental health (Checklist of somatic and psychiatric diseases, CGI), Patient wellbeing (Problem severity, GAF) |
| 1 month |
| Herrenberg |
| Baden-Württenberg |
| 71083 |
| Germany |
| Dr. Reinhold Burr | Hirrlingen | Baden-Württenberg | 72145 | Germany |
| Dr. Christoph von Ascheraden | Saint Blasien | Baden-Württenberg | 79837 | Germany |
| Dr. Barbara Haider | Aichach | Bavaria | 86551 | Germany |
| Dr. Eugen Fürmann | Augsburg | Bavaria | 86150 | Germany |
| Dr. Astrid Beck | Fürstenfeldbruck | Bavaria | 82256 | Germany |
| Dr. Winfred Dresel | Warngau | Bavaria | 83627 | Germany |
| Dr. Monika Peter-Giglio | Bad Nauheim | Hesse | 61231 | Germany |
| Dr. Andreas Weselek | Ehringshausen | Hesse | 35630 | Germany |
| Dr. Georg Wetzig | Frankfurt am Main | Hesse | 60316 | Germany |
| Dr. Christine Rose | Goslar | Lower Saxony | 38640 | Germany |
| Dr. Uta Menschikowski | Parchim | Mecklenburg-Vorpommern | 19370 | Germany |
| Dr. Georg Kramann | Achim | Niedersachen | 28832 | Germany |
| Dr. Detmar Jobst | Bonn | North Rhine-Westphalia | 53229 | Germany |
| Dr. Michel Voss | Cologne | North Rhine-Westphalia | 51065 | Germany |
| Dr. Helmut Walter | Hamm | North Rhine-Westphalia | 59065 | Germany |
| Dr. Manfred Plum | Herne | North Rhine-Westphalia | 44652 | Germany |
| Dr. Martin Burger und Dr. Wolfgang Lüttecken | Münster | North Rhine-Westphalia | 48153 | Germany |
| Dr. Astrid Weber | Koblenz | Rhineland-Palatinate | 56070 | Germany |
| Dr. Liane Arimond | Trier | Rhineland-Palatinate | 54293 | Germany |
| Dr. Maria Viehweger | Chemnitz | Saxony | 09130 | Germany |
| Dr. Ernst Soldan | Norderstedt | Schleswig-Holstein | 22846 | Germany |
| Dr. Alexander Cegla | Wenningstedt | Schleswig-Holstein | 25980 | Germany |
| Dr. Gerd Klausen | Berlin | 10115 | Germany |
| Dr. Clemens Micus | Berlin | 12043 | Germany |
| Dr. Lutz Weinrich | Berlin | 12555 | Germany |
| Dr. Wieland Tietje | Bremen | 28719 | Germany |
| Dr. Nico le Claire | Hamburg | 20095 | Germany |
| Dr. Felix Maas | Hamburg | 20357 | Germany |
| Dr. Wirkner Thiel | Hamburg | 22043 | Germany |
| Dr. Eckhard Zeigert | Hamburg | 22609 | Germany |
| Strada L, Schulte B, Schmidt CS, Verthein U, Cremer-Schaeffer P, Kruckeberg S, Reimer J. Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol. BMC Infect Dis. 2015 Dec 10;15:563. doi: 10.1186/s12879-015-1307-z. |
| Reset | Jun 7, 2024 |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Oct 1, 2019 | Oct 23, 2019 | |||
| Dec 7, 2023 | Jun 7, 2024 |
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided